Clinical Trials

500 enrolled

Breast Neoplasms

NCT07173751 2026-04-21

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07541079 2026-04-21

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

300 enrolled

Breast Neoplasms

NCT05132582 2026-04-20

HER2CLIMB-05

654 enrolled

Breast Neoplasms

NCT05780567 2026-04-17

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

1,946 enrolled

Breast Neoplasms

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07205822 2026-04-17

TB06

100 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04421963 2026-04-16

ROSY-O

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07085767 2026-04-16

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT05774951 2026-04-13

CAMBRIA-1

4,300 enrolled

Breast Neoplasms

NCT05038735 2026-04-08

EPIK-B5

234 enrolled

Breast Neoplasms

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

250 enrolled

Breast Neoplasms

NCT06764186 2026-04-08

CAPItana

101 enrolled

Breast Neoplasms

NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

BreastGynecologicThoracic

145 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT06072612 2026-04-07

BRIA-ABC

404 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06790693 2026-04-03

INAVO123

450 enrolled

Breast Neoplasms

NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

256 enrolled

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

8,000 enrolled

Breast Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast Neoplasms

NCT06312176 2026-04-02

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06982521 2026-04-02

ReDiscover-2

540 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

300 enrolled

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 3 FDA

Breast Neoplasms

NCT05894239 2026-03-31

INAVO122

230 enrolled

Breast Neoplasms

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06954961 2026-03-31

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

640 enrolled

Breast Neoplasms

NCT06492616 2026-03-27

ELEGANT

4,220 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06635447 2026-03-27

CAPItrue

258 enrolled

Breast Neoplasms, Disease Progression

NCT07354022 2026-03-27

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

912 enrolled

Breast Neoplasms

NCT05232916 2026-03-19

FLAMINGO-01

750 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT07349069 2026-03-19

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

4,800 enrolled

Breast Neoplasms

NCT00099437 2026-03-18

CONFIRM

736 enrolled 14 charts

Breast Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

624 enrolled 17 charts

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled

Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06057610 2026-03-11

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

868 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06018337 2026-03-05

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled

Breast Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 2 FDA

Breast Neoplasms

NCT04873362 2026-03-04

Astefania

1,188 enrolled

Breast Neoplasms

NCT06760637 2026-03-02

FourLight-3

1,020 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled